The Swedish-British laboratory said its diabetes treatment, Farxiga, was not effective in treating patients with severe Covid-19.

The trial of 1250 people did not reach a level of statistics sufficient to prevent mortality in these patients.

The Swedish-British laboratory AstraZeneca announced Monday that its treatment for diabetes Farxiga was not effective in treating patients with severe Covid-19, according to the first results of clinical trials.

The Farxiga trial "has not reached a statistical level sufficient" to prevent mortality, the group said in a statement.

These are the first results of the so-called phase 3 clinical trial conducted on 1,250 people, in collaboration with the American institute specializing in cardiovascular diseases Saint Luke's Mid America.

The objective was to evaluate the effectiveness of Farxiga on patients hospitalized with Covid-19 and who are at risk of developing complications, in particular those who already have other pathologies such as hypertension, diabetes or heart disease. or kidney.

>> LIVE

- Coronavirus: follow the evolution of the situation Monday April 12

Full test results will be released next May.

Development of another antibody treatment against Covid

This is a new setback for AstraZeneca, whose vaccine against Covid-19 also raises many questions, in particular with possible side effects such as cases of blood clots.

Some countries have stopped using the vaccine, while others are setting age limits.

For example, it is reserved for over 30s in the United Kingdom, where it has been used extensively.

CORONAVIRUS ESSENTIALS

> Covid-19: is there really a risk of contamination outside?

> Coronavirus: why can a PCR test be positive one month after infection?

> Are private parties really prohibited with the curfew?

> The English variant would cause slightly different symptoms

> Audio, webcams ... When technology adapts to teleworking

The distribution of serum is furthermore disrupted and suffers regular delays, as was again the case last week in the EU.

AstraZeneca is also developing an antibody treatment against Covid-19, the latest trials of which are underway worldwide.

The US government has funded the development of the drug and the group plans to deliver up to 700,000 doses to the US this year.